Over the course of six months, eating only between noon and 8 p.m. had a greater impact on weight loss and a similar effect on HbA1c levels compared with reducing energy intake by 25%, according to a small randomized trial of patients with type 2 diabetes and obesity.
Cardiometabolic factors traditionally associated with microvascular disease were not associated with risk for painful diabetic peripheral neuropathy in patients with type 1 diabetes, a European study found.
Patients with an elevated urinary albumin-to-creatinine ratio, even below 30 mg/g, were at increased risk for major adverse cardiovascular (CV) events, a post hoc analysis of the ACCORD trial found.
This month's quiz asks readers to choose a medication for a 68-year-old man with a history of type 2 diabetes, hyperlipidemia, hypertension, and aortofemoral bypass surgery 2 years ago.
Manufacturer trials reported the effects of weekly insulin and teplizumab in patients with type 1 diabetes, while recent reviews looked at preventing beta-cell loss with various therapeutics and using drugs approved for type 2 diabetes to combat chronic kidney disease in type 1.
The effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on gout in patients with type 2 diabetes or heart failure (HF) may allow reduced polypharmacy when treatment for gout is also needed, an ACP Journal Club commentary said.
In adults with BMI ≥27 kg/m2 and type 2 diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk
The new drugs known as “twincretins” represent a major breakthrough for patients with overweight or obesity, prediabetes, or diabetes, but obstacles will include supply, lack of cost-effectiveness evidence, and insurance coverage, an ACP Journal club commentary said.
Analysis of a randomized trial in South Korea found that patients randomized to rosuvastatin developed type 2 diabetes requiring medication at a rate of 7.2%, compared to 5.3% among those given atorvastatin.